| 1.33 -0.01 (-0.75%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.66  |
1-year : | 2 |
| Resists | First : | 1.42 |
Second : | 1.72 |
| Pivot price | 1.24  |
|||
| Supports | First : | 0.95 |
Second : | 0.79 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.19 |
| MA(100) : | 0.95 |
MA(250) : | 1.26 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 74.8 |
D(3) : | 78.6 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 1.9 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SLS ] has closed below upper band by 35.8%. Bollinger Bands are 37.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.39 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.31 - 1.33 | 1.33 - 1.34 |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Thu, 28 Mar 2024
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 27 Mar 2024
Should You Sell Sellas Life Sciences Group Inc (SLS) Stock Wednesday Morning? - InvestorsObserver
Tue, 26 Mar 2024
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering ... - Yahoo Finance
Tue, 19 Mar 2024
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private ... - GlobeNewswire
Fri, 15 Mar 2024
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement ... - GlobeNewswire
Thu, 14 Mar 2024
SLS Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 5,270 (K) |
| Shares Short P.Month | 4,510 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -174.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -1 |
| PEG Ratio | 0 |
| Price to Book value | -5.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|